Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection

Bone Marrow Transplant. 2000 Oct;26(7):805-8. doi: 10.1038/sj.bmt.1702600.

Abstract

The prognosis of chronic active Epstein-Barr virus infection (CAEBV) is very poor. We describe a 24-year-old male with severe CAEBV who was treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT). On admission, EBER-1 in lymphocytes infiltrating the liver, EBV-DNA in peripheral blood mononuclear cells (PBMC) and monoclonal NK cell proliferation were confirmed. After unsuccessful chemotherapy, he received an allo-PBSCT from his HLA-identical sister. Although he died of pulmonary hemorrhage on day +19, EBV-DNA was undetectable by PCR in PBMC, and the post-mortem liver showed no EBER-1-positive lymphocytes. This experience suggests that EBV-positive lymphocytes in CAEBV may be eradicated by allo-PBSCT, thereby raising the possibility of a new treatment modality. Bone Marrow Transplantation (2000) 26, 805-808.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Chronic Disease
  • DNA, Viral / blood
  • Epstein-Barr Virus Infections / genetics
  • Epstein-Barr Virus Infections / therapy*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunotherapy, Adoptive
  • Lymphocytes / virology
  • Male
  • RNA, Viral / blood
  • T-Lymphocytes, Cytotoxic / transplantation
  • Transplantation, Homologous

Substances

  • DNA, Viral
  • Epstein-Barr virus encoded RNA 1
  • RNA, Viral